目的 評價(jià)銀杏葉口服制劑聯(lián)合常規(guī)治療缺血性腦卒中的經(jīng)濟(jì)性。方法 從衛(wèi)生體系角度出發(fā)，基于1項(xiàng)隨機(jī)臨床對照研究結(jié)果，構(gòu)建長期Markov模型，模擬輕度殘疾、中重度殘疾、復(fù)發(fā)及死亡的動(dòng)態(tài)變化。對照組為化學(xué)藥常規(guī)治療，試驗(yàn)組為銀杏葉口服制劑聯(lián)合化學(xué)藥常規(guī)治療。運(yùn)用TreeAge Pro 2019軟件構(gòu)建藥物經(jīng)濟(jì)學(xué)模型并模擬分析。結(jié)果 模型模擬13周期后，試驗(yàn)組的成本和產(chǎn)出分別為202 418.71元和5.15質(zhì)量調(diào)整生命年（QALY）；對照組的成本和產(chǎn)出分別為195 982.73元和4.81 QALY。相比對照組，試驗(yàn)組的增量-成本效果比（ICER）為18 519.24元（每個(gè)QALY），小于支付意愿閾值。敏感性分析結(jié)果顯示該經(jīng)濟(jì)學(xué)評價(jià)結(jié)果穩(wěn)定。結(jié)論 對于缺血性腦卒中的治療，相比化學(xué)藥常規(guī)治療，銀杏葉口服制劑聯(lián)合化學(xué)藥常規(guī)治療為具有藥物經(jīng)濟(jì)學(xué)優(yōu)勢的治療方案。

Objective To evaluate the economics of Ginkgo biloba oral preparation combined with conventional therapy for patients with cerebral ischemic stroke. Methods From the perspective of the health system, based on the results of a randomized clinical controlled study, a long-term Markov model was constructed to simulate the dynamic changes of mild disability, moderate to severe disability, recurrence, and death. The experimental group was treated with G. biloba oral preparation combined with normal medication, and the control group was treated with normal medication alone. The cost-utility and sensitivity analysis were performed for two regimens by TreeAge Pro 2019. Results After 13 cycles of model simulation, results showed that the cost and output of oral G. biloba preparation combined with conventional therapy were 202 418.71 yuan and 5.15 QALY (quality adjusted life years), and the cost and output of the conventional therapy were 195 982.73 yuan and 4.81 QALY, respectively. Compared with control group, the incremental cost-effectiveness ratio (ICER) of the experimental group was 18 519.24 yuan/QALY, and it was less than the willingness to pay threshold. Sensitivity analysis supported the robustness of the results. Conclusion For the treatment of cerebral ischemic stroke, compared with the conventional therapy alone, Ginkgo biloba oral preparation combined with conventional therapy is a pharmacoeconomic advantageous treatment.

R971

江蘇省藥學(xué)會(huì)天晴醫(yī)院藥學(xué)基金項(xiàng)目（編號(hào)Q202028）；蘇州市第九人民醫(yī)院科研啟動(dòng)基金課題（YK202113）